Human fetuin has been considered as a biomarker for certain metabolic diseases, but its quantitative analysis by various commercial enzyme-linked immunosorbent assays (ELISA) has been found to be problematic (29), which we hypothesize may be partly related to differences in the glycosylation patterns of AHSG*1 and AHSG*2. This evidence concerns the gene AHSG and metabolic disease.